To assess whether stimulating palladin KD CAFs with TGFβ1 ligand would rescue pro-tumor CAF features, we treated palladin KD and control CAFs with recombinant TGFβ1 ligand (rTGFβ1) and assessed restoration of myofibroblastic CAF features, such as production of aligned matrices, as well as ECM-dependent PDAC cell proliferation. Here, PALD1 is linked to neoplasm.